Artiva Halts AlloNK Development, Cuts 94% of Staff, Explores Strategic Alternatives

What happened

Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a San Diego-based clinical-stage biotechnology company, said on October 27, 2026 that it is halting all further development of AlloNK (AB-101) and is initiating a process to explore strategic alternatives to maximize stockholder value, according to its Form 8-K.

The company's board approved the discontinuation on October 22, 2026, along with a plan to reduce the workforce by approximately 94% of its current employee base. Artiva calls this the Wind Down.

Artiva also disclosed preliminary cash, cash equivalents and investments of approximately $319.1 million as of September 30, 2026. The company said this figure is unaudited and may change, and that complete quarterly results will appear in its Form 10-Q for the quarter ended September 30, 2026.

The filing does not state a reason for halting AlloNK development. It says only that the discontinuation is occurring as the company conducts a process to explore strategic alternatives.

The stock reaction

Artiva shares closed at $4.2072 on the event date, down 31.7% from the prior close of $6.16, according to the price data. Volume was 6,087,369 shares, about 14.7 times the average volume of 413,973.

The Wind Down costs

Under Item 2.05 of the filing, Artiva said it cannot reasonably estimate the total costs and charges of the Wind Down at this time. It said the charges will relate primarily to contract termination and other costs tied to discontinuing its clinical trials, costs related to leases, other existing liabilities and operational closing activities, and costs related to the workforce reduction.

The company expects to complete the workforce reduction in the first quarter of 2027 and to incur a significant majority of the Wind Down costs in the fourth quarter of 2026. It said actual timing and costs depend on assumptions and may differ.

What this means

An 8-K is the form a US public company files with the SEC to report material events that shareholders should know about between regular quarterly reports. The items listed on the cover tell readers what kind of event it is. Item 2.02 covers the release of earnings or operating results; here it carried the announcement of the AlloNK halt, the strategic-alternatives process, and the preliminary cash balance. Item 2.05 covers costs associated with an exit or disposal activity, meaning a decision to stop something and wind it down. Item 9.01 attaches the exhibits, in this case the press release.

AlloNK (AB-101) is described in the filing as a non-genetically modified, allogeneic natural killer (NK) cell therapy candidate. "Allogeneic" means the cells are intended to come from a donor rather than the patient, so one manufacturing batch could in principle treat multiple patients. "Natural killer" cells are a type of immune cell. Because the filing does not say why development is stopping, this article does not either.

"Strategic alternatives" is a standard corporate phrase for a review of options that can include a merger, sale of the company or its assets, licensing deals, or other transactions. The filing says Artiva is exploring such alternatives but gives no timeline, no named counterparties, and no assurance that any transaction will result. Readers should treat the process as an open-ended review, not a completed deal.

The roughly 94% workforce reduction is the mechanical part of the Wind Down: a company stopping its clinical programs no longer needs most of the staff running them. The filing says the reduction should be complete in the first quarter of 2027, with most related costs hitting the fourth quarter of 2026. Because Artiva cannot yet estimate total Wind Down costs, the eventual charge is unknown.

The $319.1 million cash figure matters because a company winding down clinical trials must pay contract termination costs, lease obligations and severance. Artiva labels the number preliminary: it is management's estimate, has not been reviewed by its auditors, and may be revised in the Form 10-Q. That quarterly filing is the next document where fuller numbers would be expected.

The 8-K does not disclose which strategic alternatives Artiva is considering, whether it has engaged advisers, or what the halt means for the AlloNK clinical trial participants. Those details are not in the source.